Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CDX-1140 by Celldex Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Varlilumab by Celldex Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Varlilumab is under clinical development by Celldex Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
Varlilumab by Celldex Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval
Varlilumab is under clinical development by Celldex Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
CDX-1140 by Celldex Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
CDX-1140 by Celldex Therapeutics for Peritoneal Cancer: Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
CDX-1140 by Celldex Therapeutics for Fallopian Tube Cancer: Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
CDX-1140 by Celldex Therapeutics for Endometrial Cancer: Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Celldex Therapeutics's Barzolvolimab?
Barzolvolimab is a monoclonal antibody commercialized by Celldex Therapeutics, with a leading Phase III program in Chronic Urticaria Or Hives....
CDX-585 by Celldex Therapeutics for Solid Tumor: Likelihood of Approval
CDX-585 is under clinical development by Celldex Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Barzolvolimab by Celldex Therapeutics for Eosinophilic Esophagitis: Likelihood of Approval
Barzolvolimab is under clinical development by Celldex Therapeutics and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase...
Barzolvolimab by Celldex Therapeutics for Prurigo: Likelihood of Approval
Barzolvolimab is under clinical development by Celldex Therapeutics and currently in Phase II for Prurigo. According to GlobalData, Phase II...
CDX-301 by Celldex Therapeutics for Skin Cancer: Likelihood of Approval
CDX-301 is under clinical development by Celldex Therapeutics and currently in Phase I for Skin Cancer. According to GlobalData, Phase...
CDX-301 by Celldex Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
CDX-301 is under clinical development by Celldex Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
Barzolvolimab by Celldex Therapeutics for Chronic Urticaria Or Hives: Likelihood of Approval
Barzolvolimab is under clinical development by Celldex Therapeutics and currently in Phase II for Chronic Urticaria Or Hives. According to...